Pediatrics

>

Latest News

Nirsevimab for RSV Reduces Infant Hospitalizations by 82% in Real-World Study
Nirsevimab for RSV Reduces Infant Hospitalizations by 82% in Real-World Study

May 2nd 2024

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

Primary Care-Based Injury Prevention Program Reduces Pediatric Injuries: Daily Dose / image credit: ©New Africa/AdobeStock
Primary Care-Based Injury Prevention Program Reduces Pediatric Injuries: Daily Dose

April 12th 2024

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma / Image credit: ©Argus/AdobeStock
FDA Approves Benralizumab as Add-On Maintenance Therapy for Children Aged 6-11 Years with Severe Asthma

April 11th 2024

Primary Care-Based Injury Prevention Program Found to Reduce Pediatric Injuries in New Study / Image credit: ©pavel1964/AdobeStock
Primary Care-Based Injury Prevention Program Found to Reduce Pediatric Injuries in New Study

April 4th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.